<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33801336</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>02</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Skeletal Muscle in ALS: An Unappreciated Therapeutic Opportunity?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">525</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells10030525</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by the selective degeneration of upper and lower motor neurons and by the progressive weakness and paralysis of voluntary muscles. Despite intense research efforts and numerous clinical trials, it is still an incurable disease. ALS had long been considered a pure motor neuron disease; however, recent studies have shown that motor neuron protection is not sufficient to prevent the course of the disease since the dismantlement of neuromuscular junctions occurs before motor neuron degeneration. Skeletal muscle alterations have been described in the early stages of the disease, and they seem to be mainly involved in the "dying back" phenomenon of motor neurons and metabolic dysfunctions. In recent years, skeletal muscles have been considered crucial not only for the etiology of ALS but also for its treatment. Here, we review clinical and preclinical studies that targeted skeletal muscles and discuss the different approaches, including pharmacological interventions, supplements or diets, genetic modifications, and training programs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scaricamazza</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Fondazione Santa Lucia IRCCS, c/o CERC, 00143 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvatori</LastName><ForeName>Illari</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Fondazione Santa Lucia IRCCS, c/o CERC, 00143 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of Rome "La Sapienza", 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferri</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fondazione Santa Lucia IRCCS, c/o CERC, 00143 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Translational Pharmacology, National Research Council, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valle</LastName><ForeName>Cristiana</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Fondazione Santa Lucia IRCCS, c/o CERC, 00143 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Translational Pharmacology, National Research Council, 00133 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HyperALS</GrantID><Agency>Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica</Agency><Country/></Grant><Grant><GrantID>2018</GrantID><Agency>AFM-T&#xe9;l&#xe9;thon</Agency><Country/></Grant><Grant><GrantID>21021</GrantID><Agency>AFM-T&#xe9;l&#xe9;thon</Agency><Country/></Grant><Grant><GrantID>PGR01040</GrantID><Agency>Ministero della Salute</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">genetic intervention</Keyword><Keyword MajorTopicYN="N">pharmacological approaches</Keyword><Keyword MajorTopicYN="N">physical activity</Keyword><Keyword MajorTopicYN="N">skeletal muscle</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest. The funding sources had no role in the collection, analysis, and interpretation of the data of this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>3</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33801336</ArticleId><ArticleId IdType="pmc">PMC8000428</ArticleId><ArticleId IdType="doi">10.3390/cells10030525</ArticleId><ArticleId IdType="pii">cells10030525</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O., Al-chalabi A., Chio A., Corr E.M., Robberecht W., Shaw P.J., Simmons Z. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;3 doi: 10.1038/nrdp.2017.71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2019:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg L.H. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzolino M., Ferri A., Teresa Carr&#xec; M. Amyotrophic lateral sclerosis: From current developments in the laboratory to clinical implications. Antioxid. Redox Signal. 2008;10:405&#x2013;443. doi: 10.1089/ars.2007.1760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2007.1760</ArticleId><ArticleId IdType="pubmed">18370853</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi S., Cozzolino M., Carr&#xec; M.T. Proceedings of the Brain Pathology. Vol. 26. Blackwell Publishing Ltd.; Hoboken, NJ, USA: 2016. Old versus new mechanisms in the pathogenesis of ALS; pp. 276&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029354</ArticleId><ArticleId IdType="pubmed">26779612</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaarsma D., Teuling E., Haasdijk E.D., De Zeeuw C.I., Hoogenraad C.C. Neuron-specific expression of mutant superoxide dismutase is sufficient to induce amyotrophic lateral sclerosis in transgenic mice. J. Neurosci. 2008;28:2075&#x2013;2088. doi: 10.1523/JNEUROSCI.5258-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5258-07.2008</ArticleId><ArticleId IdType="pmc">PMC6671838</ArticleId><ArticleId IdType="pubmed">18305242</ArticleId></ArticleIdList></Reference><Reference><Citation>Lino M.M., Schneider C., Caroni P. Accumulation of SOD1 Mutants in Postnatal Motoneurons Does Not Cause Motoneuron Pathology or Motoneuron Disease. J. Neurosci. 2002;22:4825&#x2013;4832. doi: 10.1523/JNEUROSCI.22-12-04825.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-12-04825.2002</ArticleId><ArticleId IdType="pmc">PMC6757755</ArticleId><ArticleId IdType="pubmed">12077179</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Aucello M., Rizzuto E., Beccafico S., Mammucari C., Boncompagni S., Bonconpagni S., Belia S., Wannenes F., Nicoletti C., et al. Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab. 2008;8:425&#x2013;436. doi: 10.1016/j.cmet.2008.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2008.09.002</ArticleId><ArticleId IdType="pubmed">19046573</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L.J., Wong M. Skeletal Muscle-Restricted Expression of Human SOD1 in Transgenic Mice Causes a Fatal ALS-Like Syndrome. Front. Neurol. 2020;11 doi: 10.3389/fneur.2020.592851.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.592851</ArticleId><ArticleId IdType="pmc">PMC7767933</ArticleId><ArticleId IdType="pubmed">33381076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore E., Casola I., Dobrowolny G., Musar&#xf2; A. Neuromuscular Junction as an Entity of Nerve-Muscle Communication. Cells. 2019;8:906. doi: 10.3390/cells8080906.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8080906</ArticleId><ArticleId IdType="pmc">PMC6721719</ArticleId><ArticleId IdType="pubmed">31426366</ArticleId></ArticleIdList></Reference><Reference><Citation>Heckman C.J., Enoka R.M. Motor unit. Compr. Physiol. 2012;2:2629&#x2013;2682. doi: 10.1002/cphy.c100087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cphy.c100087</ArticleId><ArticleId IdType="pubmed">23720261</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadon-Nachum M., Melamed E., Offen D. The &#x201c;dying-back&#x201d; phenomenon of motor neurons in ALS. J. Mol. Neurosci. 2011;43:470&#x2013;477. doi: 10.1007/s12031-010-9467-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-010-9467-1</ArticleId><ArticleId IdType="pubmed">21057983</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer L.R., Culver D.G., Tennant P., Davis A.A., Wang M., Castellano-sanchez A., Khan J., Polak M.A., Glass J.D. Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Exp. Neurol. 2004;185:232&#x2013;240. doi: 10.1016/j.expneurol.2003.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fayemendy P., Marin B., Labrunie A., Boirie Y., Walrand S., Achamrah N., Co&#xeb;ffier M., Preux P.M., Lautrette G., Desport J.C., et al. Hypermetabolism is a reality in amyotrophic lateral sclerosis compared to healthy subjects. J. Neurol. Sci. 2021;420 doi: 10.1016/j.jns.2020.117257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.117257</ArticleId><ArticleId IdType="pubmed">33290920</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn F.J., Ioannides Z.A., Van Eijk R.P.A., Heggie S., Thorpe K.A., Ceslis A., Heshmat S., Henders A.K., Wray N.R., Van Den Berg L.H., et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J. Neurol. Neurosurg. Psychiatry. 2018:1016&#x2013;1023. doi: 10.1136/jnnp-2017-317887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317887</ArticleId><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri A., Coccurello R. Review Article What is &#x201c;Hyper&#x201d; in the ALS Hypermetabolism? Mediat. Inflamm. 2017;2017 doi: 10.1155/2017/7821672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/7821672</ArticleId><ArticleId IdType="pmc">PMC5610793</ArticleId><ArticleId IdType="pubmed">29081604</ArticleId></ArticleIdList></Reference><Reference><Citation>Harwood C.A., Westgate K., Gunstone S., Brage S., Wareham N.J., McDermott C.J., Shaw P.J. Long-term physical activity: An exogenous risk factor for sporadic amyotrophic lateral sclerosis? Amyotroph. Lateral Scler. Front. Degener. 2016;17:377&#x2013;384. doi: 10.3109/21678421.2016.1154575.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1154575</ArticleId><ArticleId IdType="pmc">PMC4950417</ArticleId><ArticleId IdType="pubmed">26998882</ArticleId></ArticleIdList></Reference><Reference><Citation>Pupillo E., Bianchi E., Vanacore N., Montalto C., Ricca G., Robustelli Della Cuna F.S., Fumagalli F., Castellani M., Poli F., Romeo F., et al. Increased risk and early onset of ALS in professional players from Italian Soccer Teams. Amyotroph. Lateral Scler. Front. Degener. 2020;21:403&#x2013;409. doi: 10.1080/21678421.2020.1752250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1752250</ArticleId><ArticleId IdType="pubmed">32321311</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter R.S., Rosenbohm A., Dupuis L., Brehme T., Kassubek J., Rothenbacher D., Nagel G., Ludolph A.C. Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: Results from the ALS registry Swabia. Eur. J. Epidemiol. 2017;32:901&#x2013;908. doi: 10.1007/s10654-017-0318-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-017-0318-z</ArticleId><ArticleId IdType="pubmed">28975435</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A., Lin T., Al Khleifat A., Jones A.R., Opie-Martin S., Coleman J.R.I., Shatunov A., Sproviero W., Williams K.L., Garton F., et al. Genome-wide Meta-analysis Finds the ACSL5-ZDHHC6 Locus Is Associated with ALS and Links Weight Loss to the Disease Genetics. Cell Rep. 2020;33 doi: 10.1016/j.celrep.2020.108323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108323</ArticleId><ArticleId IdType="pmc">PMC7610013</ArticleId><ArticleId IdType="pubmed">33113361</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindauer E., Dupuis L., M&#xfc;ller H.-P., Neumann H., Ludolph A.C., Kassubek J. Adipose Tissue Distribution Predicts Survival in Amyotrophic Lateral Sclerosis. PLoS ONE. 2013;8:e67783. doi: 10.1371/journal.pone.0067783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0067783</ArticleId><ArticleId IdType="pmc">PMC3694869</ArticleId><ArticleId IdType="pubmed">23826340</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakken O., Meyer H.E., Stigum H., Holm&#xf8;y T. High BMI is associated with low ALS risk: A population-based study. Neurology. 2019;93:E424&#x2013;E432. doi: 10.1212/WNL.0000000000007861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007861</ArticleId><ArticleId IdType="pubmed">31243073</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor D.M., Boulis N.M. Gene therapy for neurodegenerative diseases. Trends Mol. Med. 2015;21:504&#x2013;512. doi: 10.1016/j.molmed.2015.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2015.06.001</ArticleId><ArticleId IdType="pubmed">26122838</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel R.S., Mercuri E., Darras B.T., Connolly A.M., Kuntz N.L., Kirschner J., Chiriboga C.A., Saito K., Servais L., Tizzano E., et al. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N. Engl. J. Med. 2017;377:1723&#x2013;1732. doi: 10.1056/NEJMoa1702752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1702752</ArticleId><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri E., Darras B.T., Chiriboga C.A., Day J.W., Campbell C., Connolly A.M., Iannaccone S.T., Kirschner J., Kuntz N.L., Saito K., et al. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N. Engl. J. Med. 2018;378:625&#x2013;635. doi: 10.1056/NEJMoa1710504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1710504</ArticleId><ArticleId IdType="pubmed">29443664</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell J.R., Al-Zaidy S., Shell R., Arnold W.D., Rodino-Klapac L.R., Prior T.W., Lowes L., Alfano L., Berry K., Church K., et al. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N. Engl. J. Med. 2017;377:1713&#x2013;1722. doi: 10.1056/NEJMoa1706198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1706198</ArticleId><ArticleId IdType="pubmed">29091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A.C., Wurster C.D. Therapeutic advances in SMA. Curr. Opin. Neurol. 2019;32:777&#x2013;781. doi: 10.1097/WCO.0000000000000738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000738</ArticleId><ArticleId IdType="pubmed">31425176</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L.F.H., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: A glial cell line&#x2014;Derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260:1130&#x2013;1132. doi: 10.1126/science.8493557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8493557</ArticleId><ArticleId IdType="pubmed">8493557</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L.H., Zhang T.J., Collins F., Armes L.G. Purification and Initial Characterization of Rat B49 Glial Cell Line-Derived Neurotrophic Factor. J. Neurochem. 1994;63:758&#x2013;768. doi: 10.1046/j.1471-4159.1994.63020758.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1994.63020758.x</ArticleId><ArticleId IdType="pubmed">8035200</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson C.E., Phillips H.S., Pollock R.A., Davies A.M., Lemeulle C., Armanini M., Simpson L.C., Moffet B., Vandlen R.A., Koliatsos V.E., et al. GDNF: A potent survival factor for motoneurons present in peripheral nerve and muscle. Science. 1994;266:1062&#x2013;1064. doi: 10.1126/science.7973664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7973664</ArticleId><ArticleId IdType="pubmed">7973664</ArticleId></ArticleIdList></Reference><Reference><Citation>Oppenheim R.W., Houenou L.J., Johnson J.E., Lin L.F.H., Li L., Lo A.C., Newsome A.L., Prevette D.M., Wang S. Developing motor neurons rescued from programmed and axotomy-induced cell death by gdnf. Nature. 1995;373:344&#x2013;346. doi: 10.1038/373344a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/373344a0</ArticleId><ArticleId IdType="pubmed">7830769</ArticleId></ArticleIdList></Reference><Reference><Citation>Trupp M., Ryd&#xe9;n M., J&#xf6;rnvall H., Funakoshi H., Timmusk T., Arenas E., Ib&#xe1;&#xf1;ez C.F. Peripheral expression and biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons. J. Cell Biol. 1995;130:137&#x2013;148. doi: 10.1083/jcb.130.1.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.130.1.137</ArticleId><ArticleId IdType="pmc">PMC2120511</ArticleId><ArticleId IdType="pubmed">7790368</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Wu W., Lin L.F.H., Lei M., Oppenheim R.W., Houenou L.J. Rescue of adult mouse motoneurons from injury-induced cell death by glial cell line-derived neurotrophic factor. Proc. Natl. Acad. Sci. USA. 1995;92:9771&#x2013;9775. doi: 10.1073/pnas.92.21.9771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.21.9771</ArticleId><ArticleId IdType="pmc">PMC40884</ArticleId><ArticleId IdType="pubmed">7568215</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruven C., Badea S.R., Wong W.M., Wu W. Combination treatment with exogenous GDNF and fetal spinal cord cells results in better motoneuron survival and functional recovery after avulsion injury with delayed root reimplantation. J. Neuropathol. Exp. Neurol. 2018;77:325&#x2013;343. doi: 10.1093/jnen/nly009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nly009</ArticleId><ArticleId IdType="pubmed">29420729</ArticleId></ArticleIdList></Reference><Reference><Citation>Cintr&#xf3;n-Col&#xf3;n A.F., Almeida-Alves G., Boynton A.M., Spitsbergen J.M. GDNF synthesis, signaling, and retrograde transport in motor neurons. Cell Tissue Res. 2020;382:47&#x2013;56. doi: 10.1007/s00441-020-03287-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-020-03287-6</ArticleId><ArticleId IdType="pmc">PMC7529617</ArticleId><ArticleId IdType="pubmed">32897420</ArticleId></ArticleIdList></Reference><Reference><Citation>Alisky J.M., Davidson B.L. Gene Therapy for Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases. Hum. Gene Ther. 2000;11:2315&#x2013;2329. doi: 10.1089/104303400750038435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/104303400750038435</ArticleId><ArticleId IdType="pubmed">11096437</ArticleId></ArticleIdList></Reference><Reference><Citation>Acsadi G., Anguelov R.A., Yang H., Toth G., Thomas R., Jani A., Wang Y., Ianakova E., Mohammad S., Lewis R.A., et al. Increased survival and function of SOD1 mice after Glial cell-derived neurotrophic factor gene therapy. Hum. Gene Ther. 2002;13:1047&#x2013;1059. doi: 10.1089/104303402753812458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/104303402753812458</ArticleId><ArticleId IdType="pubmed">12067438</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki M., McHugh J., Tork C., Shelley B., Hayes A., Bellantuono I., Aebischer P., Svendsen C.N. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol. Ther. 2008;16:2002&#x2013;2010. doi: 10.1038/mt.2008.197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2008.197</ArticleId><ArticleId IdType="pmc">PMC2678899</ArticleId><ArticleId IdType="pubmed">18797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Shim J.W., Madsen J.R. VEGF signaling in neurological disorders. Int. J. Mol. Sci. 2018;19:275. doi: 10.3390/ijms19010275.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19010275</ArticleId><ArticleId IdType="pmc">PMC5796221</ArticleId><ArticleId IdType="pubmed">29342116</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosthuyse B., Moons L., Storkebaum E., Beck H., Nuyens D., Brusselmans K., Van Dorpe J., Hellings P., Gorselink M., Heymans S., et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 2001;28:131&#x2013;138. doi: 10.1038/88842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/88842</ArticleId><ArticleId IdType="pubmed">11381259</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzouz M., Ralph G.S., Storkebaum E., Walmsley L.E., Mitrophanous K.A., Kingsman S.M., Carmellet P., Mazarakis N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature. 2004;429:413&#x2013;417. doi: 10.1038/nature02544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02544</ArticleId><ArticleId IdType="pubmed">15164063</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeb J.A., Khurana T.S., Robbins J.T., Yee A.G., Fischbach G.D. Expression patterns of transmembrane and released forms of neuregulin during spinal cord and neuromuscular synapse development. Development. 1999;126:781&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">9895325</ArticleId></ArticleIdList></Reference><Reference><Citation>Esper R.M., Pankonin M.S., Loeb J.A. Neuregulins: Versatile growth and differentiation factors in nervous system development and human disease. Brain Res. Rev. 2006;51:161&#x2013;175. doi: 10.1016/j.brainresrev.2005.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresrev.2005.11.006</ArticleId><ArticleId IdType="pubmed">16412517</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricker F.R., Lago N., Balarajah S., Tsantoulas C., Tanna S., Zhu N., Fageiry S.K., Jenkins M., Garratt A.N., Birchmeier C., et al. Axonally derived neuregulin-1 is required for remyelination and regeneration after nerve injury in adulthood. J. Neurosci. 2011;31:3225&#x2013;3233. doi: 10.1523/JNEUROSCI.2568-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2568-10.2011</ArticleId><ArticleId IdType="pmc">PMC3059576</ArticleId><ArticleId IdType="pubmed">21368034</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandrock A.W., Dryer S.E., Rosen K.M., Gozani S.N., Kramer R., Theill L.E., Fischbach G.D. Maintenance of acetylcholine receptor number by neuregulins at the neuromuscular junction in vivo. Science. 1997;276:599&#x2013;603. doi: 10.1126/science.276.5312.599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.276.5312.599</ArticleId><ArticleId IdType="pubmed">9110980</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo S.T., Cole R.N., Sunn N., Phillips W.D., Noakes P.G. Neuregulin-1 potentiates agrin-induced acetylcholine: Receptor clustering through muscle-specific kinase: Phosphorylation. J. Cell Sci. 2012;125:1531&#x2013;1543. doi: 10.1242/jcs.095109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.095109</ArticleId><ArticleId IdType="pubmed">22328506</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolpowitz D., Mason T.B.A., Dietrich P., Mendelsohn M., Talmage D.A., Role L.W. Cysteine-rich domain isoforms of the Neuregulin-1 gene are required for maintenance of peripheral synapses. Neuron. 2000;25:79&#x2013;91. doi: 10.1016/S0896-6273(00)80873-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80873-9</ArticleId><ArticleId IdType="pubmed">10707974</ArticleId></ArticleIdList></Reference><Reference><Citation>Song F., Chiang P., Wang J., Ravits J., Loeb J.A. Aberrant neuregulin 1 signaling in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2012;71:104&#x2013;115. doi: 10.1097/NEN.0b013e3182423c43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3182423c43</ArticleId><ArticleId IdType="pmc">PMC3270561</ArticleId><ArticleId IdType="pubmed">22249457</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf2;dol-Caballero G., Garc&#xed;a-Lareu B., Verd&#xe9;s S., Ariza L., S&#xe1;nchez-Brualla I., Brocard F., Bosch A., Navarro X., Herrando-Grabulosa M. Therapeutic Role of Neuregulin 1 Type III in SOD1-Linked Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2020;17:1048&#x2013;1060. doi: 10.1007/s13311-019-00811-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-019-00811-7</ArticleId><ArticleId IdType="pmc">PMC7609630</ArticleId><ArticleId IdType="pubmed">31965551</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R., Mart&#xed;nez-Muriana A., Leiva T., Gregorio D., Ariza L., Morell M., Esteban-P&#xe9;rez J., Garc&#xed;a-Redondo A., Calvo A.C., Atencia-Cibreiro G., et al. Neuregulin-1 promotes functional improvement by enhancing collateral sprouting in SOD1G93A ALS mice and after partial muscle denervation. Neurobiol. Dis. 2016;95:168&#x2013;178. doi: 10.1016/j.nbd.2016.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.07.023</ArticleId><ArticleId IdType="pubmed">27461051</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf2;dol-Caballero G., Herrando-Grabulosa M., Garc&#xed;a-Lareu B., Solanes N., Verd&#xe9;s S., Osta R., Francos-Quijorna I., L&#xf3;pez-Vales R., Calvo A.C., Bosch A., et al. Gene therapy for overexpressing Neuregulin 1 type I in skeletal muscles promotes functional improvement in the SOD1G93A ALS mice. Neurobiol. Dis. 2020;137:104793. doi: 10.1016/j.nbd.2020.104793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.104793</ArticleId><ArticleId IdType="pubmed">32032731</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffler J.-P., Picchiarelli G., Dupuis L., Gonzalez De Aguilar J.-L. The Role of Skeletal Muscle in Amyotrophic Lateral Sclerosis. Brain Pathol. 2016;26:227&#x2013;236. doi: 10.1111/bpa.12350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12350</ArticleId><ArticleId IdType="pmc">PMC8029271</ArticleId><ArticleId IdType="pubmed">26780251</ArticleId></ArticleIdList></Reference><Reference><Citation>Burden S.J. Building the vertebrate neuromuscular synapse. J. Neurobiol. 2002;53:501&#x2013;511. doi: 10.1002/neu.10137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/neu.10137</ArticleId><ArticleId IdType="pubmed">12436415</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbst R. MuSk function during health and disease. Neurosci. Lett. 2020;716:134676. doi: 10.1016/j.neulet.2019.134676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2019.134676</ArticleId><ArticleId IdType="pubmed">31811897</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez Cruz P.M., Cossins J., Beeson D., Vincent A. The Neuromuscular Junction in Health and Disease: Molecular Mechanisms Governing Synaptic Formation and Homeostasis. Front. Mol. Neurosci. 2020;13:610964. doi: 10.3389/fnmol.2020.610964.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.610964</ArticleId><ArticleId IdType="pmc">PMC7744297</ArticleId><ArticleId IdType="pubmed">33343299</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesser B.A., Henschel O., Witzemann V. Synapse disassembly and formation of new synapses in postnatal muscle upon conditional inactivation of MuSK. Mol. Cell. Neurosci. 2006;31:470&#x2013;480. doi: 10.1016/j.mcn.2005.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2005.10.020</ArticleId><ArticleId IdType="pubmed">16337809</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong X.C., Barzaghi P., Ruegg M.A. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep. 2004;5:183&#x2013;188. doi: 10.1038/sj.embor.7400065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400065</ArticleId><ArticleId IdType="pmc">PMC1298976</ArticleId><ArticleId IdType="pubmed">14749715</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Garc&#xed;a M.J., Burden S.J. Increasing MuSK Activity Delays Denervation and Improves Motor Function in ALS Mice. Cell Rep. 2012;2:497&#x2013;502. doi: 10.1016/j.celrep.2012.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2012.08.004</ArticleId><ArticleId IdType="pmc">PMC3462266</ArticleId><ArticleId IdType="pubmed">22939980</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue A., Setoguchi K., Matsubara Y., Okada K., Sato N., Iwakura Y., Higuchi O., Yamanashi Y. Dok-7 activates the muscle receptor kinase MuSK and shapes synapse formation. Sci. Signal. 2009;2:ra7. doi: 10.1126/scisignal.2000113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2000113</ArticleId><ArticleId IdType="pubmed">19244212</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeson D., Higuchi O., Palace J., Cossins J., Spearman H., Maxwell S., Newsom-Davis J., Burke G., Fawcett P., Motomura M., et al. Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science. 2006;313:1975&#x2013;1978. doi: 10.1126/science.1130837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1130837</ArticleId><ArticleId IdType="pubmed">16917026</ArticleId></ArticleIdList></Reference><Reference><Citation>Arimura S., Okada T., Tezuka T., Chiyo T., Kasahara Y., Yoshimura T., Motomura M., Yoshida N., Beeson D., Takeda S., et al. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction. Science. 2014;345:1505&#x2013;1508. doi: 10.1126/science.1250744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1250744</ArticleId><ArticleId IdType="pubmed">25237101</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe9;jat A., Decostre V., Li J., Renou L., Kesari A., Hanta&#xef; D., Stewart C.L., Xiao X., Hoffman E., Bonne G., et al. Lamin A/C&#x2014;Mediated neuromuscular junction defects in Emery-Dreifuss muscular dystrophy. J. Cell Biol. 2009;184:31&#x2013;44. doi: 10.1083/jcb.200811035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200811035</ArticleId><ArticleId IdType="pmc">PMC2615092</ArticleId><ArticleId IdType="pubmed">19124654</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyoshi S., Tezuka T., Arimura S., Tomono T., Okada T., Yamanashi Y. DOK 7 gene therapy enhances motor activity and life span in ALS model mice. EMBO Mol. Med. 2017;9:880&#x2013;889. doi: 10.15252/emmm.201607298.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201607298</ArticleId><ArticleId IdType="pmc">PMC5494517</ArticleId><ArticleId IdType="pubmed">28490573</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams A.H., Valdez G., Moresi V., Qi X., McAnally J., Elliott J.L., Bassel-Duby R., Sanes J.R., Olson E.N. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science. 2009;326:1549&#x2013;1554. doi: 10.1126/science.1181046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1181046</ArticleId><ArticleId IdType="pmc">PMC2796560</ArticleId><ArticleId IdType="pubmed">20007902</ArticleId></ArticleIdList></Reference><Reference><Citation>DI Pietro L., Baranzini M., Berardinelli M.G., Lattanzi W., Monforte M., Tasca G., Conte A., Logroscino G., Michetti F., Ricci E., et al. Potential therapeutic targets for ALS: MIR206, MIR208b and MIR499 are modulated during disease progression in the skeletal muscle of patients. Sci. Rep. 2017;7 doi: 10.1038/s41598-017-10161-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-10161-z</ArticleId><ArticleId IdType="pmc">PMC5573384</ArticleId><ArticleId IdType="pubmed">28842714</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegoraro V., Marozzo R., Angelini C. MicroRNAs and HDAC4 protein expression in the skeletal muscle of ALS patients. Clin. Neuropathol. 2020;39:105&#x2013;114. doi: 10.5414/NP301233.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/NP301233</ArticleId><ArticleId IdType="pubmed">32000889</ArticleId></ArticleIdList></Reference><Reference><Citation>Lle Bruneteau G., Simonet T., Phanie Bauch&#xe9; S., Mandjee N., Malfatti E., Girard E., Tanguy M.-L., Behin A., D&#xe9; F., Khiami R., et al. Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: Potential role in reinnervation ability and disease progression. Brain. 2013;136:2359&#x2013;2368. doi: 10.1093/brain/awt164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt164</ArticleId><ArticleId IdType="pubmed">23824486</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen T.J., Waddell D.S., Barrientos T., Lu Z., Feng G., Cox G.A., Bodine S.C., Yao T.P. The histone deacetylase HDAC4 connects neural activity to muscle transcriptional reprogramming. J. Biol. Chem. 2007;282:33752&#x2013;33759. doi: 10.1074/jbc.M706268200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M706268200</ArticleId><ArticleId IdType="pubmed">17873280</ArticleId></ArticleIdList></Reference><Reference><Citation>Moresi V., Williams A.H., Meadows E., Flynn J.M., Potthoff M.J., McAnally J., Shelton J.M., Backs J., Klein W.H., Richardson J.A., et al. Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell. 2010;143:35&#x2013;45. doi: 10.1016/j.cell.2010.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.09.004</ArticleId><ArticleId IdType="pmc">PMC2982779</ArticleId><ArticleId IdType="pubmed">20887891</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi M.C., Cohen T.J., Barrientos T., Wang B., Li M., Simmons B.J., Yang J.S., Cox G.A., Zhao Y., Yao T.P. A Direct HDAC4-MAP Kinase Crosstalk Activates Muscle Atrophy Program. Mol. Cell. 2012;47:122&#x2013;132. doi: 10.1016/j.molcel.2012.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2012.04.025</ArticleId><ArticleId IdType="pmc">PMC3398192</ArticleId><ArticleId IdType="pubmed">22658415</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonvicino D., Felici R., Ranieri G., Caramelli R., Lapucci A., Cavone L., Muzzi M., Di Pietro L., Bernardini C., Zwergel C., et al. Effects of Class II-Selective Histone Deacetylase Inhibitor on Neuromuscular Function and Disease Progression in SOD1-ALS Mice. Neuroscience. 2018;379:228&#x2013;238. doi: 10.1016/j.neuroscience.2018.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2018.03.022</ArticleId><ArticleId IdType="pubmed">29588251</ArticleId></ArticleIdList></Reference><Reference><Citation>Pigna E., Simonazzi E., Sanna K., Bernadzki K.M., Proszynski T., Heil C., Palacios D., Adamo S., Moresi V. Histone deacetylase 4 protects from denervation and skeletal muscle atrophy in a murine model of amyotrophic lateral sclerosis. EBioMedicine. 2019;40:717&#x2013;732. doi: 10.1016/j.ebiom.2019.01.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.01.038</ArticleId><ArticleId IdType="pmc">PMC6414308</ArticleId><ArticleId IdType="pubmed">30713114</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Martone J., Lepore E., Casola I., Petrucci A., Inghilleri M., Morlando M., Colantoni A., Scicchitano B.M., Calvo A., et al. A longitudinal study defined circulating microRNAs as reliable biomarkers for disease prognosis and progression in ALS human patients. Cell Death Discov. 2021;7 doi: 10.1038/s41420-020-00397-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-020-00397-6</ArticleId><ArticleId IdType="pmc">PMC7801652</ArticleId><ArticleId IdType="pubmed">33431881</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegedus J., Putman C.T., Tyreman N., Gordon T. Preferential motor unit loss in the SOD1 G93A transgenic mouse model of amyotrophic lateral sclerosis. J. Physiol. 2008;586:3337&#x2013;3351. doi: 10.1113/jphysiol.2007.149286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2007.149286</ArticleId><ArticleId IdType="pmc">PMC2538809</ArticleId><ArticleId IdType="pubmed">18467368</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon T., Putman C.T., Hegedus J. Amyotrophic lateral sclerosis-evidence of early denervation of fast-twitch muscles. Basic Appl. Myol. 2007;17:4.</Citation></Reference><Reference><Citation>Di Pietro L., Lattanzi W., Bernardini C. Skeletal muscle microRNAs as key players in the pathogenesis of amyotrophic lateral sclerosis. Int. J. Mol. Sci. 2018;19:1534. doi: 10.3390/ijms19051534.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19051534</ArticleId><ArticleId IdType="pmc">PMC5983603</ArticleId><ArticleId IdType="pubmed">29786645</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma G., Wang Y., Li Y., Cui L., Zhao Y., Zhao B., Li K. MiR-206, a key modulator of skeletal muscle development and disease. Int. J. Biol. Sci. 2015;11:345&#x2013;352. doi: 10.7150/ijbs.10921.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.10921</ArticleId><ArticleId IdType="pmc">PMC4323374</ArticleId><ArticleId IdType="pubmed">25678853</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J.F., Tao Y., Li J., Deng Z., Yan Z., Xiao X., Wang D.Z. microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7. J. Cell Biol. 2010;190:867&#x2013;879. doi: 10.1083/jcb.200911036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200911036</ArticleId><ArticleId IdType="pmc">PMC2935565</ArticleId><ArticleId IdType="pubmed">20819939</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey B.K., Gagan J., Dutta A. miR-206 and -486 Induce Myoblast Differentiation by Downregulating Pax7. Mol. Cell. Biol. 2011;31:203&#x2013;214. doi: 10.1128/MCB.01009-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.01009-10</ArticleId><ArticleId IdType="pmc">PMC3019853</ArticleId><ArticleId IdType="pubmed">21041476</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes S.M., Taylor J.M., Tapscott S.J., Gurley C.M., Carter W.J., Peterson C.A. Selective accumulation of MyoD and myogenin mRNAs in fast and slow adult skeletal muscle is controlled by innervation and hormones. Development. 1993;118:1137&#x2013;1147.</Citation><ArticleIdList><ArticleId IdType="pubmed">8269844</ArticleId></ArticleIdList></Reference><Reference><Citation>Maves L., Waskiewicz A.J., Paul B., Cao Y., Tyler A., Moens C.B., Tapscott S.J. Pbx homeodomain proteins direct Myod activity to promote fast-muscle differentiation. Development. 2007;134:3371&#x2013;3382. doi: 10.1242/dev.003905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.003905</ArticleId><ArticleId IdType="pubmed">17699609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekmark M., Rana Z.A., Stewart G., Hardie D.G., Gundersen K. De-phosphorylation of MyoD is linking nerve-evoked activity to fast myosin heavy chain expression in rodent adult skeletal muscle. J. Physiol. 2007;584:637&#x2013;650. doi: 10.1113/jphysiol.2007.141457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2007.141457</ArticleId><ArticleId IdType="pmc">PMC2277165</ArticleId><ArticleId IdType="pubmed">17761773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes S.M., Chi M.M.Y., Lowry O.H., Gundersen K. Myogenin induces a shift of enzyme activity from glycolytic to oxidative metabolism in muscles of transgenic mice. J. Cell Biol. 1999;145:633&#x2013;642. doi: 10.1083/jcb.145.3.633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.145.3.633</ArticleId><ArticleId IdType="pmc">PMC2185087</ArticleId><ArticleId IdType="pubmed">10225962</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekmark M., Gr&#xf8;nevik E., Schjerling P., Gundersen K. Myogenin induces higher oxidative capacity in pre-existing mouse muscle fibres after somatic DNA transfer. J. Physiol. 2003;548:259&#x2013;269. doi: 10.1113/jphysiol.2002.036228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2002.036228</ArticleId><ArticleId IdType="pmc">PMC2342785</ArticleId><ArticleId IdType="pubmed">12598590</ArticleId></ArticleIdList></Reference><Reference><Citation>Park K.H.J., Franciosi S., Leavitt B.R. Postnatal muscle modification by myogenic factors modulates neuropathology and survival in an ALS mouse model. Nat. Commun. 2013;4 doi: 10.1038/ncomms3906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3906</ArticleId><ArticleId IdType="pmc">PMC4965267</ArticleId><ArticleId IdType="pubmed">24346342</ArticleId></ArticleIdList></Reference><Reference><Citation>Peggion C., Massimino M.L., Biancotto G., Angeletti R., Reggiani C., Sorgato M.C., Bertoli A., Stella R., Stella R. Absolute quantification of myosin heavy chain isoforms by selected reaction monitoring can underscore skeletal muscle changes in a mouse model of amyotrophic lateral sclerosis. Anal. Bioanal. Chem. 2017 doi: 10.1007/s00216-016-0160-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-016-0160-2</ArticleId><ArticleId IdType="pubmed">28078418</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Lepore E., Martini M., Barberi L., Nunn A., Scicchitano B.M., Musar&#xf2; A. Metabolic Changes Associated with Muscle Expression of SOD1 G93A. Front. Physiol. 2018;9:831. doi: 10.3389/fphys.2018.00831.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2018.00831</ArticleId><ArticleId IdType="pmc">PMC6048270</ArticleId><ArticleId IdType="pubmed">30042688</ArticleId></ArticleIdList></Reference><Reference><Citation>Palamiuc L., Schlagowski A., Ngo S.T., Vernay A., Dirrig-Grosch S., Henriques A., Boutillier A.-L., Zoll J., Echaniz-Laguna A., Loeffler J.-P., et al. A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol. Med. 2015;7:526&#x2013;546. doi: 10.15252/emmm.201404433.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201404433</ArticleId><ArticleId IdType="pmc">PMC4492815</ArticleId><ArticleId IdType="pubmed">25820275</ArticleId></ArticleIdList></Reference><Reference><Citation>Scaricamazza S., Salvatori I., Giacovazzo G., Loeffler J.P., Ren&#xe8; F., Rosina M., Quessada C., Proietti D., Heil C., Rossi S., et al. Skeletal-muscle metabolic reprogramming in ALS-SOD1 mice predates disease onset and is a promising therapeutical target. iScience. 2020;23:101087. doi: 10.1016/j.isci.2020.101087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101087</ArticleId><ArticleId IdType="pmc">PMC7200935</ArticleId><ArticleId IdType="pubmed">32371370</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattiazzi M., D&#x2019;Aurelio M., Gajewski C.D., Martushova K., Kiaei M., Flint Beal M., Manfredi G. Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J. Biol. Chem. 2002;277:29626&#x2013;29633. doi: 10.1074/jbc.M203065200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M203065200</ArticleId><ArticleId IdType="pubmed">12050154</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzolino M., Ferri A., Ferraro E., Rotilio G., Cecconi F., Carr&#xec; M.T. Apaf1 mediates apoptosis and mitochondrial damage induced by mutant human SOD1s typical of familial amyotrophic lateral sclerosis. Neurobiol. Dis. 2006;21:69&#x2013;79. doi: 10.1016/j.nbd.2005.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2005.06.010</ArticleId><ArticleId IdType="pubmed">16046141</ArticleId></ArticleIdList></Reference><Reference><Citation>Handschin C. Regulation of skeletal muscle cell plasticity by the peroxisome proliferator-activated receptor &#x3b3; coactivator 1&#x3b1;. J. Recept. Signal Transduct. 2010;30:376&#x2013;384. doi: 10.3109/10799891003641074.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10799891003641074</ArticleId><ArticleId IdType="pubmed">20178454</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J., Handschin C., Spiegelman B.M. Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 2005;1:361&#x2013;370. doi: 10.1016/j.cmet.2005.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2005.05.004</ArticleId><ArticleId IdType="pubmed">16054085</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Cruz S., Parone P.A., Lopes V.S., Lillo C., McAlonis-Downes M., Lee S.K., Vetto A.P., Petrosyan S., Marsala M., Murphy A.N., et al. Elevated PGC-1&#x3b1; activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS. Cell Metab. 2012;15:778&#x2013;786. doi: 10.1016/j.cmet.2012.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2012.03.019</ArticleId><ArticleId IdType="pmc">PMC3565468</ArticleId><ArticleId IdType="pubmed">22560226</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Gonzalez de Aguilar J.L., Echaniz-Laguna A., Eschbach J., Rene F., Oudart H., Halter B., Huze C., Schaeffer L., Bouillaud F., et al. Muscle mitochondrial uncoupling dismantles neuromuscular junction and triggers distal degeneration of motor neurons. PLoS ONE. 2009;4:e5390. doi: 10.1371/journal.pone.0005390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0005390</ArticleId><ArticleId IdType="pmc">PMC2671839</ArticleId><ArticleId IdType="pubmed">19404401</ArticleId></ArticleIdList></Reference><Reference><Citation>Natale G., Lenzi P., Lazzeri G., Falleni A., Biagioni F., Ryskalin L., Fornai F. Compartment-dependent mitochondrial alterations in experimental als, the effects of mitophagy and mitochondriogenesis. Front. Cell. Neurosci. 2015;9:434. doi: 10.3389/fncel.2015.00434.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00434</ArticleId><ArticleId IdType="pmc">PMC4635226</ArticleId><ArticleId IdType="pubmed">26594150</ArticleId></ArticleIdList></Reference><Reference><Citation>Parone P.A., Da Cruz S., Han J.S., McAlonis-Downes M., Vetto A.P., Lee S.K., Tseng E., Cleveland D.W. Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis. J. Neurosci. 2013;33:4657&#x2013;4671. doi: 10.1523/JNEUROSCI.1119-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1119-12.2013</ArticleId><ArticleId IdType="pmc">PMC3711648</ArticleId><ArticleId IdType="pubmed">23486940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffoli R., Bartalucci A., Frati A., Fornai F. Ultrastructural studies of ALS mitochondria connect altered function and permeability with defects of mitophagy and mitochondriogenesis. Front. Cell. Neurosci. 2015;9:341. doi: 10.3389/fncel.2015.00341.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00341</ArticleId><ArticleId IdType="pmc">PMC4555074</ArticleId><ArticleId IdType="pubmed">26388731</ArticleId></ArticleIdList></Reference><Reference><Citation>Riis S., Murray J.B., O&#x2019;Connor R. IGF-1 Signalling Regulates Mitochondria Dynamics and Turnover through a Conserved GSK-3&#x3b2;&#x2013;Nrf2&#x2013;BNIP3 Pathway. Cells. 2020;9:147. doi: 10.3390/cells9010147.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9010147</ArticleId><ArticleId IdType="pmc">PMC7016769</ArticleId><ArticleId IdType="pubmed">31936236</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad S.S., Ahmad K., Lee E.J., Lee Y.H., Choi I. Implications of Insulin-Like Growth Factor-1 in Skeletal Muscle and Various Diseases. Cells. 2020;9:1773. doi: 10.3390/cells9081773.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9081773</ArticleId><ArticleId IdType="pmc">PMC7465464</ArticleId><ArticleId IdType="pubmed">32722232</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida T., Delafontaine P. Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy. Cells. 2020;9:1970. doi: 10.3390/cells9091970.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9091970</ArticleId><ArticleId IdType="pmc">PMC7564605</ArticleId><ArticleId IdType="pubmed">32858949</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y.H., Song J.L., Delafontaine P., Godard M.P. The therapeutic potential of IGF-I in skeletal muscle repair. Trends Endocrinol. Metab. 2013;24:310&#x2013;319. doi: 10.1016/j.tem.2013.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2013.03.004</ArticleId><ArticleId IdType="pmc">PMC3732824</ArticleId><ArticleId IdType="pubmed">23628587</ArticleId></ArticleIdList></Reference><Reference><Citation>Musaro A., Rosenthal N. The Role of local Insulin-like Growth Factor-1 Isoforms in the Pathophysiology of Skeletal Muscle. Curr. Genom. 2002;3:149&#x2013;162. doi: 10.2174/1389202023350462.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389202023350462</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Giacinti C., Pelosi L., Nicoletti C., Winn N., Barberi L., Molinaro M., Rosenthal N., Musar&#xf2; A. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. J. Cell Biol. 2005;168:193&#x2013;199. doi: 10.1083/jcb.200407021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200407021</ArticleId><ArticleId IdType="pmc">PMC2171577</ArticleId><ArticleId IdType="pubmed">15657392</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G., Aucello M., Molinaro M., Musar&#xf2; A. Local expression of mIgf-1 modulates ubiquitin, caspase and CDK5 expression in skeletal muscle of an ALS mouse model. Neurol. Res. 2008;30:131&#x2013;136. doi: 10.1179/174313208X281235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/174313208X281235</ArticleId><ArticleId IdType="pubmed">18397603</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel G., Peter R.S., Rosenbohm A., Koenig W., Dupuis L., Rothenbacher D., Ludolph A.C. Association of Insulin-like Growth Factor 1 Concentrations with Risk for and Prognosis of Amyotrophic Lateral Sclerosis&#x2014;Results from the ALS Registry Swabia. Sci. Rep. 2020;10:736. doi: 10.1038/s41598-020-57744-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-57744-x</ArticleId><ArticleId IdType="pmc">PMC6971302</ArticleId><ArticleId IdType="pubmed">31959864</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo S.T., Steyn F.J. The interplay between metabolic homeostasis and neurodegeneration: Insights into the neurometabolic nature of amyotrophic lateral sclerosis. Cell Regen. 2015;4:4&#x2013;5. doi: 10.1186/s13619-015-0019-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13619-015-0019-6</ArticleId><ArticleId IdType="pmc">PMC4551561</ArticleId><ArticleId IdType="pubmed">26322226</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma S., Black S.M. Carnitine homeostasis, mitochondrial function and cardiovascular disease. Drug Discov. Today Dis. Mech. 2009;6:e31&#x2013;e39. doi: 10.1016/j.ddmec.2009.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ddmec.2009.02.001</ArticleId><ArticleId IdType="pmc">PMC2905823</ArticleId><ArticleId IdType="pubmed">20648231</ArticleId></ArticleIdList></Reference><Reference><Citation>Fielding R., Riede L., Lugo J.P., Bellamine A. L-carnitine supplementation in recovery after exercise. Nutrients. 2018;10:349. doi: 10.3390/nu10030349.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu10030349</ArticleId><ArticleId IdType="pmc">PMC5872767</ArticleId><ArticleId IdType="pubmed">29534031</ArticleId></ArticleIdList></Reference><Reference><Citation>Montesano A., Senesi P., Luzi L., Benedini S., Terruzzi I. Potential therapeutic role of L-carnitine in skeletal muscle oxidative stress and atrophy conditions. Oxid. Med. Cell. Longev. 2015;2015 doi: 10.1155/2015/646171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/646171</ArticleId><ArticleId IdType="pmc">PMC4369953</ArticleId><ArticleId IdType="pubmed">25838869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kira Y., Nishikawa M., Ochi A., Sato E., Inoue M. L-Carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis. Brain Res. 2006;1070:206&#x2013;214. doi: 10.1016/j.brainres.2005.11.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2005.11.052</ArticleId><ArticleId IdType="pubmed">16412993</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E., Pupillo E., Bonito V., Buzzi P., Caponnetto C., Chi&#xf2; A., Corbo M., Giannini F., Inghilleri M., La Bella V., et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph. Lateral Scler. Front. Degener. 2013;14:397&#x2013;405. doi: 10.3109/21678421.2013.764568.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.764568</ArticleId><ArticleId IdType="pubmed">23421600</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Oudart H., Ren&#xe9; F., Gonzalez De Aguilar J.L., Loeffler J.P. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model. Proc. Natl. Acad. Sci. USA. 2004;101:11159&#x2013;11164. doi: 10.1073/pnas.0402026101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402026101</ArticleId><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo E., O&#x2019;Conner A.G., Barrows J.M., Shreiner D.D., Birchak G.J., Zarnescu D.C. Medium-chain fatty acids, beta-hydroxybutyric acid and genetic modulation of the carnitine shuttle are protective in a drosophila model of ALS based on TDP-43. Front. Mol. Neurosci. 2018;11 doi: 10.3389/fnmol.2018.00182.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00182</ArticleId><ArticleId IdType="pmc">PMC5990617</ArticleId><ArticleId IdType="pubmed">29904341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A.C., Dorst J., Dreyhaupt J., Weishaupt J.H., Kassubek J., Weiland U., Meyer T., Petri S., Hermann A., Emmer A., et al. Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis. Ann. Neurol. 2020;87:206&#x2013;216. doi: 10.1002/ana.25661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25661</ArticleId><ArticleId IdType="pubmed">31849093</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimar&#xe3;es-Ferreira L. Role of the phosphocreatine system on energetic homeostasis in skeletal and cardiac muscles. Einstein. 2014;12:126&#x2013;131. doi: 10.1590/S1679-45082014RB2741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/S1679-45082014RB2741</ArticleId><ArticleId IdType="pmc">PMC4898252</ArticleId><ArticleId IdType="pubmed">24728259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallimann T., Tokarska-Schlattner M., Schlattner U. The creatine kinase system and pleiotropic effects of creatine. Amino Acids. 2011;40:1271&#x2013;1296. doi: 10.1007/s00726-011-0877-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00726-011-0877-3</ArticleId><ArticleId IdType="pmc">PMC3080659</ArticleId><ArticleId IdType="pubmed">21448658</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon S., Jenkins D. Factors affecting the rate of phosphocreatine resynthesis following intense exercise. Sport. Med. 2002;32:761&#x2013;784. doi: 10.2165/00007256-200232120-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00007256-200232120-00002</ArticleId><ArticleId IdType="pubmed">12238940</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz A., Andersson D.C., Yu J., Norman B., Sandstr&#xf6;m M.E., Wieringa B., Westerblad H. Contraction-mediated glycogenolysis in mouse skeletal muscle lacking creatine kinase: The role of phosphorylase b activation. J. Physiol. 2003;553:523&#x2013;531. doi: 10.1113/jphysiol.2003.051078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2003.051078</ArticleId><ArticleId IdType="pmc">PMC2343558</ArticleId><ArticleId IdType="pubmed">12963789</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarnopolsky M.A. Caffeine and Creatine Use in Sport. Ann. Nutr. Metab. 2010;57:1&#x2013;8. doi: 10.1159/000322696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000322696</ArticleId><ArticleId IdType="pubmed">21346331</ArticleId></ArticleIdList></Reference><Reference><Citation>Klivenyi P., Ferrante R.J., Matthews R.T., Bogdanov M.B., Klein A.M., Andreassen O.A., Mueller G., Wermer M., Kaddurah-Daouk R., Beal M.F. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 1999;5:347&#x2013;350. doi: 10.1038/6568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/6568</ArticleId><ArticleId IdType="pubmed">10086395</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreassen O.A., Jenkins B.G., Dedeoglu A., Ferrante K.L., Bogdanov M.B., Kaddurah-Daouk R., Beal M.F. Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J. Neurochem. 2001;77:383&#x2013;390. doi: 10.1046/j.1471-4159.2001.00188.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2001.00188.x</ArticleId><ArticleId IdType="pubmed">11299300</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow R.J., Turnbull J., Da Silva S., Jiang F., Tarnopolsky M.A. Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience. 2003;119:661&#x2013;667. doi: 10.1016/S0306-4522(03)00212-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(03)00212-4</ArticleId><ArticleId IdType="pubmed">12809687</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott S., Kranz J.E., Cole J., Lincecum J.M., Thompson K., Kelly N., Bostrom A., Theodoss J., Al-Nakhala B.M., Vieira F.G., et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph. Lateral Scler. 2008;9:4&#x2013;15. doi: 10.1080/17482960701856300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701856300</ArticleId><ArticleId IdType="pubmed">18273714</ArticleId></ArticleIdList></Reference><Reference><Citation>Groeneveld G.J., Veldink J.H., Van der Tweel I., Kalmijn S., Beijer C., De Visser M., Wokke J.H.J., Franssen H., Van den Berg L.H. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol. 2003;53:437&#x2013;445. doi: 10.1002/ana.10554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10554</ArticleId><ArticleId IdType="pubmed">12666111</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu S., Macklin E.A., Jackson K.E., Simpson E., Mahoney K., Yu H., Walker J., Simmons Z., David W.S., Barkhaus P.E., et al. Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2020;21:15&#x2013;23. doi: 10.1080/21678421.2019.1672750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1672750</ArticleId><ArticleId IdType="pubmed">31608711</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld J., King R.M., Jackson C.E., Bedlack R.S., Barohn R.J., Dick A., Phillips L.H., Chapin J., Gelinas D.F., Lou J.S. Creatine monohydrate in ALS: Effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph. Lateral Scler. 2008;9:266&#x2013;272. doi: 10.1080/17482960802028890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802028890</ArticleId><ArticleId IdType="pmc">PMC2631354</ArticleId><ArticleId IdType="pubmed">18608103</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender A., Klopstock T. Creatine for neuroprotection in neurodegenerative disease: End of story? Amino Acids. 2016;48:1929&#x2013;1940. doi: 10.1007/s00726-015-2165-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00726-015-2165-0</ArticleId><ArticleId IdType="pubmed">26748651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccanti M., Pozzilli V., Cambieri C., Libonati L., Onesti E., Frasca V., Fiorini I., Petrucci A., Garibaldi M., Palma E., et al. Creatine Kinase and Progression Rate in Amyotrophic Lateral Sclerosis. Cells. 2020;9:1174. doi: 10.3390/cells9051174.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9051174</ArticleId><ArticleId IdType="pmc">PMC7291088</ArticleId><ArticleId IdType="pubmed">32397320</ArticleId></ArticleIdList></Reference><Reference><Citation>Miquel E., Cassina A., Mart&#xed;nez-Palma L., Bolatto C., Tr&#xed;as E., Gandelman M., Radi R., Barbeito L., Cassina P. Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motor performance in inherited amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e34776. doi: 10.1371/journal.pone.0034776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034776</ArticleId><ArticleId IdType="pmc">PMC3318006</ArticleId><ArticleId IdType="pubmed">22509356</ArticleId></ArticleIdList></Reference><Reference><Citation>DeAngelo A.B., George M.H., House D.E. Hepatocarcinogenicity in the male B6C3F1 mouse following a lifetime exposure to dichloroacetic acid in the drinking water: Dose-response determination and modes of action. J. Toxicol. Environ. Heal. Part A. 1999;58:485&#x2013;507. doi: 10.1080/009841099157115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/009841099157115</ArticleId><ArticleId IdType="pubmed">10632141</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen L., J&#xf8;rgensen L.H., Bech R.D., Frandsen U., Schr&#xf8;der H.D. Skeletal Muscle Remodelling as a Function of Disease Progression in Amyotrophic Lateral Sclerosis. Biomed Res. Int. 2016;2016:5930621. doi: 10.1155/2016/5930621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/5930621</ArticleId><ArticleId IdType="pmc">PMC4852332</ArticleId><ArticleId IdType="pubmed">27195289</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo Y.E., Ko C.P. Dihydrotestosterone ameliorates degeneration in muscle, axons and motoneurons and improves motor function in amyotrophic lateral sclerosis model mice. PLoS ONE. 2012;7:e37258. doi: 10.1371/journal.pone.0037258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0037258</ArticleId><ArticleId IdType="pmc">PMC3351454</ArticleId><ArticleId IdType="pubmed">22606355</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen D., Cui C., Duan W., Wang W., Wang Y., Liu Y., Li Z., Li C. The role of insulin-like growth factor 1 in ALS cell and mouse models: A mitochondrial protector. Brain Res. Bull. 2019;144:1&#x2013;13. doi: 10.1016/j.brainresbull.2018.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2018.09.015</ArticleId><ArticleId IdType="pubmed">30414993</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappello V., Vezzoli E., Righi M., Fossati M., Mariotti R., Crespi A., Patruno M., Bentivoglio M., Pietrini G., Francolini M. Analysis of neuromuscular junctions and effects of anabolic steroid administration in the SOD1G93A mouse model of ALS. Mol. Cell. Neurosci. 2012;51:12&#x2013;21. doi: 10.1016/j.mcn.2012.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2012.07.003</ArticleId><ArticleId IdType="pubmed">22800606</ArticleId></ArticleIdList></Reference><Reference><Citation>Galbiati M., Onesto E., Zito A., Crippa V., Rusmini P., Mariotti R., Bentivoglio M., Bendotti C., Poletti A. The anabolic/androgenic steroid nandrolone exacerbates gene expression modifications induced by mutant SOD1 in muscles of mice models of amyotrophic lateral sclerosis. Pharmacol. Res. 2012;65:221&#x2013;230. doi: 10.1016/j.phrs.2011.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2011.12.001</ArticleId><ArticleId IdType="pmc">PMC3272141</ArticleId><ArticleId IdType="pubmed">22178654</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters S., Zitzelsperger E., Kuespert S., Iberl S., Heydn R., Johannesen S., Petri S., Aigner L., Thal D.R., Hermann A., et al. The TGF-&#x3b2; system as a potential pathogenic player in disease modulation of amyotrophic lateral sclerosis. Front. Neurol. 2017;8 doi: 10.3389/fneur.2017.00669.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00669</ArticleId><ArticleId IdType="pmc">PMC5736544</ArticleId><ArticleId IdType="pubmed">29326641</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnieu A., Carnac G., Vernus B. Myostatin in the Pathophysiology of Skeletal Muscle. Curr. Genom. 2007;8:415&#x2013;422. doi: 10.2174/138920207783591672.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138920207783591672</ArticleId><ArticleId IdType="pmc">PMC2647158</ArticleId><ArticleId IdType="pubmed">19412331</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobin J.F., Celeste A.J. Myostatin, a negative regulator of muscle mass: Implications for muscle degenerative diseases. Curr. Opin. Pharmacol. 2005;5:328&#x2013;332. doi: 10.1016/j.coph.2005.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2005.01.011</ArticleId><ArticleId IdType="pubmed">15907921</ArticleId></ArticleIdList></Reference><Reference><Citation>Trendelenburg A.U., Meyer A., Rohner D., Boyle J., Hatakeyama S., Glass D.J. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am. J. Physiol. Cell Physiol. 2009;296:1258&#x2013;1270. doi: 10.1152/ajpcell.00105.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00105.2009</ArticleId><ArticleId IdType="pubmed">19357233</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzbaur E.L.F., Howland D.S., Weber N., Wallace K., She Y., Kwak S., Tchistiakova L.A., Murphy E., Hinson J., Karim R., et al. Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis. Neurobiol. Dis. 2006;23:697&#x2013;707. doi: 10.1016/j.nbd.2006.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.05.009</ArticleId><ArticleId IdType="pubmed">16837207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmers T.A., Davies M.V., Koniaris L.G., Haynes P., Esquela A.F., Tomkinson K.N., McPherron A.C., Wolfman N.M., Lee S.J. Induction of cachexia in mice by systemically administered myostatin. Science. 2002;296:1486&#x2013;1488. doi: 10.1126/science.1069525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1069525</ArticleId><ArticleId IdType="pubmed">12029139</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirruccello-Straub M., Jackson J., Wawersik S., Webster M.T., Salta L., Long K., McConaughy W., Capili A., Boston C., Carven G.J., et al. Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci. Rep. 2018;8 doi: 10.1038/s41598-018-20524-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-20524-9</ArticleId><ArticleId IdType="pmc">PMC5797207</ArticleId><ArticleId IdType="pubmed">29396542</ArticleId></ArticleIdList></Reference><Reference><Citation>Lightfoot A.P., Cooper R.G. The role of myokines in muscle health and disease. Curr. Opin. Rheumatol. 2016;28:661&#x2013;666. doi: 10.1097/BOR.0000000000000337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000337</ArticleId><ArticleId IdType="pubmed">27548653</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan K., Gao X., Zhu D. The clinical relevance and mechanism of skeletal muscle wasting. Clin. Nutr. 2021;40:27&#x2013;37. doi: 10.1016/j.clnu.2020.07.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2020.07.029</ArticleId><ArticleId IdType="pubmed">32788088</ArticleId></ArticleIdList></Reference><Reference><Citation>Tasca E., Pegoraro V., Merico A., Angelini C. Circulating microRNAs as biomarkers of muscle differentiation and atrophy in ALS. Clin. Neuropathol. 2016;35:22&#x2013;30. doi: 10.5414/NP300889.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/NP300889</ArticleId><ArticleId IdType="pubmed">26588026</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison B.M., Lachey J.L., Warsing L.C., Ting B.L., Pullen A.E., Underwood K.W., Kumar R., Sako D., Grinberg A., Wong V., et al. A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 2009;217:258&#x2013;268. doi: 10.1016/j.expneurol.2009.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2009.02.017</ArticleId><ArticleId IdType="pubmed">19285073</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondulich M.K., Jolinon N., Osborne G.F., Smith E.J., Rattray I., Neueder A., Sathasivam K., Ahmed M., Ali N., Benjamin A.C., et al. Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington&#x2019;s disease mice. Sci. Rep. 2017;7:14275. doi: 10.1038/s41598-017-14290-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-14290-3</ArticleId><ArticleId IdType="pmc">PMC5660167</ArticleId><ArticleId IdType="pubmed">29079832</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose F.F., Mattis V.B., Rindt H., Lorson C.L. Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. Hum. Mol. Genet. 2009;18:997&#x2013;1005. doi: 10.1093/hmg/ddn426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn426</ArticleId><ArticleId IdType="pmc">PMC2649020</ArticleId><ArticleId IdType="pubmed">19074460</ArticleId></ArticleIdList></Reference><Reference><Citation>Jokic N., Gonzalez De Aguilar J.-L., Dimou L., Lin S., Fergani A., Ruegg M.A., Schwab M.E., Dupuis L., Loeffler J.-P. The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model. EMBO Rep. 2003 doi: 10.1038/sj.embor.7400826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400826</ArticleId><ArticleId IdType="pmc">PMC1679784</ArticleId><ArticleId IdType="pubmed">17039253</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat P.F., Bruneteau G., Gonzalez De Aguilar J.L., Dupuis L., Jokic N., Salachas F., Le Forestier N., Echaniz-Laguna A., Dubourg O., Hauw J.J., et al. Muscle Nogo-A expression is a prognostic marker in lower motor neuron syndromes. Ann. Neurol. 2007;62:15&#x2013;20. doi: 10.1002/ana.21122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21122</ArticleId><ArticleId IdType="pubmed">17455292</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V., Genge A., van den Berg L.H., Robberecht W., Ludolph A., Chio A., Kim S.H., Leigh P.N., Kiernan M.C., Shefner J.M., et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:208&#x2013;216. doi: 10.1016/S1474-4422(16)30399-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)30399-4</ArticleId><ArticleId IdType="pubmed">28139349</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantor S., Zhang W., Delestr&#xe9;e N., Rem&#xe9;dio L., Mentis G.Z., Burden S.J. Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody. Elife. 2018;7 doi: 10.7554/eLife.34375.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.34375</ArticleId><ArticleId IdType="pmc">PMC5837562</ArticleId><ArticleId IdType="pubmed">29460776</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta-Ghosh A., Dominguez S.L., Xie L., Barck K.H., Jiang Z., Earr T., Imperio J., Phu L., Budayeva H.G., Kirkpatrick D.S., et al. Muscle specific kinase (MuSK) activation preserves neuromuscular junctions in the diaphragm but is not sufficient to provide a functional benefit in the SOD1G93A mouse model of ALS. Neurobiol. Dis. 2019;124:340&#x2013;352. doi: 10.1016/j.nbd.2018.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.12.002</ArticleId><ArticleId IdType="pubmed">30528255</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma E., Reyes-Ruiz J.M., Lopergolo D., Roseti C., Bertollini C., Ruffolo G., Cifelli P., Onesti E., Limatola C., Miledi R., et al. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. Proc. Natl. Acad. Sci. USA. 2016;113:3060&#x2013;3065. doi: 10.1073/pnas.1600251113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1600251113</ArticleId><ArticleId IdType="pmc">PMC4801305</ArticleId><ArticleId IdType="pubmed">26929355</ArticleId></ArticleIdList></Reference><Reference><Citation>Deflorio C., Palma E., Conti L., Roseti C., Manteca A., Giacomelli E., Catalano M., Limatola C., Inghilleri M., Grassi F. Riluzole blocks human muscle acetylcholine receptors. J. Physiol. 2012;590:2519&#x2013;2528. doi: 10.1113/jphysiol.2012.230201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2012.230201</ArticleId><ArticleId IdType="pmc">PMC3424768</ArticleId><ArticleId IdType="pubmed">22431338</ArticleId></ArticleIdList></Reference><Reference><Citation>Collibee S.E., Bergnes G., Muci A., Browne W.F., Garard M., Hinken A.C., Russell A.J., Suehiro I., Hartman J., Kawas R., et al. Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator. ACS Med. Chem. Lett. 2018;9:354&#x2013;358. doi: 10.1021/acsmedchemlett.7b00546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsmedchemlett.7b00546</ArticleId><ArticleId IdType="pmc">PMC5900333</ArticleId><ArticleId IdType="pubmed">29670700</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwee D.T., Kennedy A., Ryans J., Russell A.J., Jia Z., Hinken A.C., Morgans D.J., Malik F.I., Jasper J.R. Fast Skeletal Muscle Troponin Activator tirasemtiv Increases Muscle Function and Performance in the B6SJL-SOD1G93A ALS Mouse Model. PLoS ONE. 2014;9:e96921. doi: 10.1371/journal.pone.0096921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0096921</ArticleId><ArticleId IdType="pmc">PMC4013064</ArticleId><ArticleId IdType="pubmed">24805850</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Cudkowicz M.E., Hardiman O., Cockroft B.M., Lee J.H., Malik F.I., Meng L., Rudnicki S.A., Wolff A.A., Andrews J.A. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 2019;20:584&#x2013;594. doi: 10.1080/21678421.2019.1612922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1612922</ArticleId><ArticleId IdType="pubmed">31081694</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Andrews J.A., Genge A., Jackson C., Lechtzin N., Miller T.M., Cockroft B.M., Meng L., Wei J., Wolff A.A., et al. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotroph. Lateral Scler. Front. Degener. 2020 doi: 10.1080/21678421.2020.1822410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1822410</ArticleId><ArticleId IdType="pubmed">32969758</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A., Shaw P., Leigh P.N., Van Den Berg L., Hardiman O., Ludolph A., Aho V.V., Sarapohja T., Kuoppam&#xe4;ki M. Oral levosimendan in amyotrophic lateral sclerosis: A phase II multicentre, randomised, double-blind, placebo-controlled trial. J. Neurol. Neurosurg. Psychiatry. 2019;90 doi: 10.1136/jnnp-2018-320288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-320288</ArticleId><ArticleId IdType="pmc">PMC6817985</ArticleId><ArticleId IdType="pubmed">31315908</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez D., Rebolledo D.L., Correa L.M., Court F.A., Cerpa W., Lipson K.E., Van Zundert B., Brandan E. The inhibition of CTGF/CCN2 activity improves muscle and locomotor function in a murine ALS model. Hum. Mol. Genet. 2018;27:2913&#x2013;2926. doi: 10.1093/hmg/ddy204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddy204</ArticleId><ArticleId IdType="pubmed">29860398</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez D., Brandan E. CTGF/CCN2 from Skeletal Muscle to Nervous System: Impact on Neurodegenerative Diseases. Mol. Neurobiol. 2019;56:5911&#x2013;5916. doi: 10.1007/s12035-019-1490-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1490-9</ArticleId><ArticleId IdType="pubmed">30689195</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Zhang N., Chu H.Y., Yu Y., Zhang Z.K., Zhang G., Zhang B.T. Connective Tissue Growth Factor: From Molecular Understandings to Drug Discovery. Front. Cell Dev. Biol. 2020;8:1239. doi: 10.3389/fcell.2020.593269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.593269</ArticleId><ArticleId IdType="pmc">PMC7658337</ArticleId><ArticleId IdType="pubmed">33195264</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales M.G., Gutierrez J., Cabello-Verrugio C., Cabrera D., Lipson K.E., Goldschmeding R., Brandan E. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy. Hum. Mol. Genet. 2013;22:4938&#x2013;4951. doi: 10.1093/hmg/ddt352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt352</ArticleId><ArticleId IdType="pubmed">23904456</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes P.J. Theophylline. Pharmaceuticals. 2010;3:725&#x2013;747. doi: 10.3390/ph3030725.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph3030725</ArticleId><ArticleId IdType="pmc">PMC4033977</ArticleId><ArticleId IdType="pubmed">27713276</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsdell J. Use of theophylline in the treatment of COPD. Chest. 1995;107:206S&#x2013;209S. doi: 10.1378/chest.107.5_Supplement.206S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.107.5_Supplement.206S</ArticleId><ArticleId IdType="pubmed">7743828</ArticleId></ArticleIdList></Reference><Reference><Citation>Cazzola M., Matera M.G. The effect of doxofylline in asthma and COPD. Respir. Med. 2020;164:105904. doi: 10.1016/j.rmed.2020.105904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2020.105904</ArticleId><ArticleId IdType="pubmed">32094104</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue J.F. Therapeutic responses in asthma and COPD: Bronchodilators. Chest. 2004;126:125S&#x2013;137S. doi: 10.1378/chest.126.2_suppl_1.125S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.126.2_suppl_1.125S</ArticleId><ArticleId IdType="pubmed">15302773</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu T.-J., Liu Y.-C., Chu C.-M., Hu H.-C., Kao K.-C. Effects of theophylline therapy on respiratory muscle strength in patients with prolonged mechanical ventilation. Medicine. 2019;98:e13982. doi: 10.1097/MD.0000000000013982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000013982</ArticleId><ArticleId IdType="pmc">PMC6336648</ArticleId><ArticleId IdType="pubmed">30633180</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffman P.L., Belsh J.M. Effect of Inspiratory Resistance and Theophylline on Respiratory Muscle Strength in Patients with Amyotrophic Lateral Sclerosis. Am. Rev. Respir. Dis. 1989;139:1418&#x2013;1423. doi: 10.1164/ajrccm/139.6.1418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm/139.6.1418</ArticleId><ArticleId IdType="pubmed">2729751</ArticleId></ArticleIdList></Reference><Reference><Citation>Berto M.C., Filha S.C., Camelier A., Rosa F.W., De Souza Bulle Oliveira A., Jardim J.R. Acute action of aminophylline in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 2007;115:301&#x2013;305. doi: 10.1111/j.1600-0404.2007.00643.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.2007.00643.x</ArticleId><ArticleId IdType="pubmed">17489939</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbrizio P., Apolloni S., Bianchi A., Salvatori I., Valle C., Lanzuolo C., Bendotti C., Nardo G., Volont&#xe9; C. P2X7 activation enhances skeletal muscle metabolism and regeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis. Brain Pathol. 2020;30:272&#x2013;282. doi: 10.1111/bpa.12774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12774</ArticleId><ArticleId IdType="pmc">PMC7065186</ArticleId><ArticleId IdType="pubmed">31376190</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraro E., Giammarioli A.M., Chiandotto S., Spoletini I., Rosano G. Exercise-induced skeletal muscle remodeling and metabolic adaptation: Redox signaling and role of autophagy. Antioxid. Redox Signal. 2014;21:154&#x2013;176. doi: 10.1089/ars.2013.5773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2013.5773</ArticleId><ArticleId IdType="pmc">PMC4048572</ArticleId><ArticleId IdType="pubmed">24450966</ArticleId></ArticleIdList></Reference><Reference><Citation>Saraulli D., Costanzi M., Mastrorilli V., Farioli-Vecchioli S. The Long Run: Neuroprotective Effects of Physical Exercise on Adult Neurogenesis from Youth to Old Age. Curr. Neuropharmacol. 2017;15:519&#x2013;533. doi: 10.2174/1570159X14666160412150223.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X14666160412150223</ArticleId><ArticleId IdType="pmc">PMC5543673</ArticleId><ArticleId IdType="pubmed">27000776</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillon A., Nielsen K., Steel C., Cornwall J., Sheard P. Exercise attenuates age-associated changes in motoneuron number, nucleocytoplasmic transport proteins and neuromuscular health. GeroScience. 2018;40:177&#x2013;192. doi: 10.1007/s11357-018-0020-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-018-0020-4</ArticleId><ArticleId IdType="pmc">PMC5964256</ArticleId><ArticleId IdType="pubmed">29736782</ArticleId></ArticleIdList></Reference><Reference><Citation>Rygiel K.A., Picard M., Turnbull D.M. The ageing neuromuscular system and sarcopenia: A mitochondrial perspective. J. Physiol. 2016;594:4499&#x2013;4512. doi: 10.1113/JP271212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP271212</ArticleId><ArticleId IdType="pmc">PMC4983621</ArticleId><ArticleId IdType="pubmed">26921061</ArticleId></ArticleIdList></Reference><Reference><Citation>Sailani M.R., Halling J.F., M&#xf8;ller H.D., Lee H., Plomgaard P., Pilegaard H., Snyder M.P., Regenberg B. Lifelong physical activity is associated with promoter hypomethylation of genes involved in metabolism, myogenesis, contractile properties and oxidative stress resistance in aged human skeletal muscle. Sci. Rep. 2019;9 doi: 10.1038/s41598-018-37895-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-37895-8</ArticleId><ArticleId IdType="pmc">PMC6397284</ArticleId><ArticleId IdType="pubmed">30824849</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruegsegger G.N., Booth F.W. Health benefits of exercise. Cold Spring Harb. Perspect. Med. 2018;8 doi: 10.1101/cshperspect.a029694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a029694</ArticleId><ArticleId IdType="pmc">PMC6027933</ArticleId><ArticleId IdType="pubmed">28507196</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolis di Robilant V., Scardigli R., Strimpakos G., Tirone F., Middei S., Scopa C., De Bardi M., Battistini L., Saraulli D., Farioli Vecchioli S. Running-Activated Neural Stem Cells Enhance Subventricular Neurogenesis and Improve Olfactory Behavior in p21 Knockout Mice. Mol. Neurobiol. 2019;56:7534&#x2013;7556. doi: 10.1007/s12035-019-1590-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1590-6</ArticleId><ArticleId IdType="pubmed">31062248</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastrorilli V., Scopa C., Saraulli D., Costanzi M., Scardigli R., Rouault J.P., Farioli-Vecchioli S., Tirone F. Physical exercise rescues defective neural stem cells and neurogenesis in the adult subventricular zone of Btg1 knockout mice. Brain Struct. Funct. 2017;222:2855&#x2013;2876. doi: 10.1007/s00429-017-1376-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00429-017-1376-4</ArticleId><ArticleId IdType="pubmed">28247022</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers S.K., Deminice R., Ozdemir M., Yoshihara T., Bomkamp M.P., Hyatt H. Exercise-induced oxidative stress: Friend or foe? J. Sport Heal. Sci. 2020;9:415&#x2013;425. doi: 10.1016/j.jshs.2020.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jshs.2020.04.001</ArticleId><ArticleId IdType="pmc">PMC7498668</ArticleId><ArticleId IdType="pubmed">32380253</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteiro-Junior R.S., De Tarso Maciel-Pinheiro P., Da Matta Mello Portugal E., Da Silva Figueiredo L.F., Terra R., Carneiro L.S.F., Rodrigues V.D., Nascimento O.J.M., Deslandes A.C., Laks J. Effect of exercise on inflammatory profile of older persons: Systematic review and meta-analyses. J. Phys. Act. Heal. 2018;15:64&#x2013;71. doi: 10.1123/jpah.2016-0735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1123/jpah.2016-0735</ArticleId><ArticleId IdType="pubmed">28771081</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb R., Hughes M.G., Thomas A.W., Morris K. The ability of exercise-associated oxidative stress to trigger redox-sensitive signalling responses. Antioxidants. 2017;6:63. doi: 10.3390/antiox6030063.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox6030063</ArticleId><ArticleId IdType="pmc">PMC5618091</ArticleId><ArticleId IdType="pubmed">28796154</ArticleId></ArticleIdList></Reference><Reference><Citation>Simioni C., Zauli G., Martelli A.M., Vitale M., Sacchetti G., Gonelli A., Neri L.M. Oxidative stress: Role of physical exercise and antioxidant nutraceuticals in adulthood and aging. Oncotarget. 2018;9:17181&#x2013;17198. doi: 10.18632/oncotarget.24729.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.24729</ArticleId><ArticleId IdType="pmc">PMC5908316</ArticleId><ArticleId IdType="pubmed">29682215</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayegh A.L.C., Degani-Costa L.H. Effects of exercise training on endothelial and diastolic age-related dysfunctions: A new view of an old problem. J. Physiol. 2017;595:4591&#x2013;4592. doi: 10.1113/JP274531.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP274531</ArticleId><ArticleId IdType="pmc">PMC5509845</ArticleId><ArticleId IdType="pubmed">28466473</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotta K., Chen B., Behnke B.J., Ghosh P., Stabley J.N., Bramy J.A., Sepulveda J.L., Delp M.D., Muller-Delp J.M. Exercise training reverses age-induced diastolic dysfunction and restores coronary microvascular function. J. Physiol. 2017;595:3703&#x2013;3719. doi: 10.1113/JP274172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP274172</ArticleId><ArticleId IdType="pmc">PMC5471361</ArticleId><ArticleId IdType="pubmed">28295341</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata S., Fujimoto N., Hastings J.L., Carrick-Ranson G., Bhella P.S., Hearon C.M., Levine B.D. The effect of lifelong exercise frequency on arterial stiffness. J. Physiol. 2018;596:2783&#x2013;2795. doi: 10.1113/JP275301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP275301</ArticleId><ArticleId IdType="pmc">PMC6046080</ArticleId><ArticleId IdType="pubmed">29781119</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebelo-Marques A., Lages A.D.S., Andrade R., Ribeiro C.F., Mota-Pinto A., Carrilho F., Espregueira-Mendes J. Aging hallmarks: The benefits of physical exercise. Front. Endocrinol. 2018;9:258. doi: 10.3389/fendo.2018.00258.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2018.00258</ArticleId><ArticleId IdType="pmc">PMC5980968</ArticleId><ArticleId IdType="pubmed">29887832</ArticleId></ArticleIdList></Reference><Reference><Citation>Puterman E., Lin J., Blackburn E., O&#x2019;Donovan A., Adler N., Epel E. The power of exercise: Buffering the effect of chronic stress on telomere length. PLoS ONE. 2010;5 doi: 10.1371/journal.pone.0010837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0010837</ArticleId><ArticleId IdType="pmc">PMC2877102</ArticleId><ArticleId IdType="pubmed">20520771</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyckelsma V.L., Levinger I., McKenna M.J., Formosa L.E., Ryan M.T., Petersen A.C., Anderson M.J., Murphy R.M. Preservation of skeletal muscle mitochondrial content in older adults: Relationship between mitochondria, fibre type and high-intensity exercise training. J. Physiol. 2017;595:3345&#x2013;3359. doi: 10.1113/JP273950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP273950</ArticleId><ArticleId IdType="pmc">PMC5451733</ArticleId><ArticleId IdType="pubmed">28251664</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg M., Blackwell J.R., Damsgaard R., Jones A.M., Hellsten Y., Mortensen S.P. Lifelong physical activity prevents an age-related reduction in arterial and skeletal muscle nitric oxide bioavailability in humans. J. Physiol. 2012;590:5361&#x2013;5370. doi: 10.1113/jphysiol.2012.239053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2012.239053</ArticleId><ArticleId IdType="pmc">PMC3515824</ArticleId><ArticleId IdType="pubmed">22890714</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph A.M., Adhihetty P.J., Leeuwenburgh C. Beneficial effects of exercise on age-related mitochondrial dysfunction and oxidative stress in skeletal muscle. J. Physiol. 2016;594:5105&#x2013;5123. doi: 10.1113/JP270659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP270659</ArticleId><ArticleId IdType="pmc">PMC5023701</ArticleId><ArticleId IdType="pubmed">26503074</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahl R.E., Andersen P.R., Gronbaek K., Morville T.H., Rosenkilde M., Rasmusen H.K., Poulsen S.S., Prats C., Dela F., Helge J.W. Repeated excessive exercise attenuates the anti-inflammatory effects of exercise in older men. Front. Physiol. 2017;8 doi: 10.3389/fphys.2017.00407.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2017.00407</ArticleId><ArticleId IdType="pmc">PMC5479888</ArticleId><ArticleId IdType="pubmed">28690546</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Cabrera M.C., Vi&#xf1;a J., Ji L.L. Interplay of oxidants and antioxidants during exercise: Implications for muscle health. Phys. Sportsmed. 2009;37:116&#x2013;123. doi: 10.3810/psm.2009.12.1749.</Citation><ArticleIdList><ArticleId IdType="doi">10.3810/psm.2009.12.1749</ArticleId><ArticleId IdType="pubmed">20048548</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreras I., Yuruker S., Aytan N., Hossain L., Choi J.K., Jenkins B.G., Kowall N.W., Dedeoglu A. Moderate exercise delays the motor performance decline in a transgenic model of ALS. Brain Res. 2010;1313:192&#x2013;201. doi: 10.1016/j.brainres.2009.11.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2009.11.051</ArticleId><ArticleId IdType="pmc">PMC2892864</ArticleId><ArticleId IdType="pubmed">19968977</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebetanz D., Hagemann K., Von Lewinski F., Kahler E., Paulus W. Extensive exercise is not harmful in amyotrophic lateral sclerosis. Eur. J. Neurosci. 2004;20:3115&#x2013;3120. doi: 10.1111/j.1460-9568.2004.03769.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2004.03769.x</ArticleId><ArticleId IdType="pubmed">15579165</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaspar B.K., Frost L.M., Christian L., Umapathi P., Gage F.H. Synergy of insulin-like growth factor-1 and exercise in amyotrophic lateral sclerosis. Ann. Neurol. 2005;57:649&#x2013;655. doi: 10.1002/ana.20451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20451</ArticleId><ArticleId IdType="pubmed">15852403</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett E.J., Mead R.J., Azzouz M., Shaw P.J., Grierson A.J. Early detection of motor dysfunction in the SOD1G93A mouse model of amyotrophic lateral sclerosis (ALS) using home cage running wheels. PLoS ONE. 2014;9:e107918. doi: 10.1371/journal.pone.0107918.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0107918</ArticleId><ArticleId IdType="pmc">PMC4182307</ArticleId><ArticleId IdType="pubmed">25268710</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney D.J., Rodriguez C., Devries M., Yasuda N., Tarnopolsky M.A. Effects of high-intensity endurance exercise training in the G93A mouse model of amyotrophic lateral sclerosis. Muscle Nerve. 2004;29:656&#x2013;662. doi: 10.1002/mus.20004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20004</ArticleId><ArticleId IdType="pubmed">15116368</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkinezos I.G., Hernandez D., Bradley W.G., Moraes C.T. Regular exercise is beneficial to a mouse model of amyotrophic lateral sclerosis. Ann. Neurol. 2003;53:804&#x2013;807. doi: 10.1002/ana.10597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10597</ArticleId><ArticleId IdType="pubmed">12783429</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink J.H., B&#xe4;r P.R., Joosten E.A.J., Otten M., Wokke J.H.J., Van Den Berg L.H. Sexual differences in onset of disease and response to exercise in a transgenic model of ALS. Neuromuscul. Disord. 2003;13:737&#x2013;743. doi: 10.1016/S0960-8966(03)00104-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-8966(03)00104-4</ArticleId><ArticleId IdType="pubmed">14561497</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbugino L., Golini E., Giuliani A., Mandillo S. Prolonged voluntary running negatively affects survival and disease prognosis of male SOD1G93A low-copy transgenic mice. Front. Behav. Neurosci. 2018;12:275. doi: 10.3389/fnbeh.2018.00275.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnbeh.2018.00275</ArticleId><ArticleId IdType="pmc">PMC6243076</ArticleId><ArticleId IdType="pubmed">30483078</ArticleId></ArticleIdList></Reference><Reference><Citation>Deforges S., Branchu J., Biondi O., Grondard C., Pariset C., L&#xe9;colle S., Lopes P., Vidal P.-P., Chanoine C., Charbonnier F. Motoneuron survival is promoted by specific exercise in a mouse model of amyotrophic lateral sclerosis. J. Physiol. 2009;587:3561&#x2013;3572. doi: 10.1113/jphysiol.2009.169748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2009.169748</ArticleId><ArticleId IdType="pmc">PMC2742281</ArticleId><ArticleId IdType="pubmed">19491245</ArticleId></ArticleIdList></Reference><Reference><Citation>Just-Borr&#xe0;s L., Hurtado E., Cilleros-Ma&#xf1;&#xe9; V., Biondi O., Charbonnier F., Tom&#xe0;s M., Garcia N., Tom&#xe0;s J., Lanuza M.A. Running and swimming prevent the deregulation of the BDNF/TrkB neurotrophic signalling at the neuromuscular junction in mice with amyotrophic lateral sclerosis. Cell. Mol. Life Sci. 2020;77:3027&#x2013;3040. doi: 10.1007/s00018-019-03337-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-019-03337-5</ArticleId><ArticleId IdType="pubmed">31646358</ArticleId></ArticleIdList></Reference><Reference><Citation>Flis D.J., Dzik K., Kaczor J.J., Halon-Golabek M., Antosiewicz J., Wieckowski M.R., Ziolkowski W. Swim training modulates skeletal muscle energy metabolism, oxidative stress, and mitochondrial cholesterol content in amyotrophic lateral sclerosis mice. Oxid. Med. Cell. Longev. 2018;2018:5940748. doi: 10.1155/2018/5940748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/5940748</ArticleId><ArticleId IdType="pmc">PMC5924974</ArticleId><ArticleId IdType="pubmed">29849903</ArticleId></ArticleIdList></Reference><Reference><Citation>Flis D.J., Dzik K., Kaczor J.J., Cieminski K., Halon-Golabek M., Antosiewicz J., Wieckowski M.R., Ziolkowski W. Swim training modulates mouse skeletal muscle energy metabolism and ameliorates reduction in grip strength in a mouse model of amyotrophic lateral sclerosis. Int. J. Mol. Sci. 2019;20:233. doi: 10.3390/ijms20020233.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20020233</ArticleId><ArticleId IdType="pmc">PMC6359093</ArticleId><ArticleId IdType="pubmed">30634386</ArticleId></ArticleIdList></Reference><Reference><Citation>Desseille C., Deforges S., Biondi O., Houdebine L., D&#x2019;Amico D., Lamazi&#xe8;re A., Caradeuc C., Bertho G., Bruneteau G., Weill L., et al. Specific physical exercise improves energetic metabolism in the skeletal muscle of amyotrophic-lateral- sclerosis mice. Front. Mol. Neurosci. 2017;10:332. doi: 10.3389/fnmol.2017.00332.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00332</ArticleId><ArticleId IdType="pmc">PMC5655117</ArticleId><ArticleId IdType="pubmed">29104532</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijssen J., Comley L.H., Hedlund E. Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133:863&#x2013;885. doi: 10.1007/s00401-017-1708-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1708-8</ArticleId><ArticleId IdType="pmc">PMC5427160</ArticleId><ArticleId IdType="pubmed">28409282</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradhan J., Noakes P.G., Bellingham M.C. The Role of Altered BDNF/TrkB Signaling in Amyotrophic Lateral Sclerosis. Front. Cell. Neurosci. 2019;13:368. doi: 10.3389/fncel.2019.00368.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00368</ArticleId><ArticleId IdType="pmc">PMC6700252</ArticleId><ArticleId IdType="pubmed">31456666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu P., Kalb R.G. BDNF heightens the sensitivity of motor neurons to excitotoxic insults through activation of TrkB. J. Neurochem. 2003;84:1421&#x2013;1430. doi: 10.1046/j.1471-4159.2003.01599.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.01599.x</ArticleId><ArticleId IdType="pubmed">12614342</ArticleId></ArticleIdList></Reference><Reference><Citation>Mojsilovic-Petrovic J., Jeong G.B., Crocker A., Arneja A., David S., Russell D., Kalb R.G. Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors. J. Neurosci. 2006;26:9250&#x2013;9263. doi: 10.1523/JNEUROSCI.1856-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1856-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674510</ArticleId><ArticleId IdType="pubmed">16957081</ArticleId></ArticleIdList></Reference><Reference><Citation>Park D., Kwak S.G., Park J.S., Choo Y.J., Chang M.C. Can Therapeutic Exercise Slow Down Progressive Functional Decline in Patients with Amyotrophic Lateral Sclerosis? A Meta-Analysis. Front. Neurol. 2020;11:853. doi: 10.3389/fneur.2020.00853.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00853</ArticleId><ArticleId IdType="pmc">PMC7438585</ArticleId><ArticleId IdType="pubmed">32903629</ArticleId></ArticleIdList></Reference><Reference><Citation>Musar&#xf2; A., Dobrowolny G., Cambieri C., Onesti E., Ceccanti M., Frasca V., Pisano A., Cerbelli B., Lepore E., Ruffolo G., et al. Neuromuscular magnetic stimulation counteracts muscle decline in ALS patients: Results of a randomized, double-blind, controlled study. Sci. Rep. 2019;9 doi: 10.1038/s41598-019-39313-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-39313-z</ArticleId><ArticleId IdType="pmc">PMC6391419</ArticleId><ArticleId IdType="pubmed">30808899</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman M.H.B., Seelen M., de Jong S.W., Dorresteijn K.R.I.S., van Doormaal P.T.C., van der Kooi A.J., de Visser M., Schelhaas H.J., van den Berg L.H., Veldink J.H. Lifetime physical activity and the risk of amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2013;84:976&#x2013;981. doi: 10.1136/jnnp-2012-304724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304724</ArticleId><ArticleId IdType="pubmed">23418211</ArticleId></ArticleIdList></Reference><Reference><Citation>Siciliano G., Pastorini E., Pasquali L., Manca M.L., Iudice A., Murri L. Impaired oxidative metabolism in exercising muscle from ALS patients. J. Neurol. Sci. 2001;191:61&#x2013;65. doi: 10.1016/S0022-510X(01)00620-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(01)00620-7</ArticleId><ArticleId IdType="pubmed">11676993</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanfranconi F., Ferri A., Corna G., Bonazzi R., Lunetta C., Silani V., Riva N., Rigamonti A., Maggiani A., Ferrarese C., et al. Inefficient skeletal muscle oxidative function flanks impaired motor neuron recruitment in Amyotrophic Lateral Sclerosis during exercise. Sci. Rep. 2017;7 doi: 10.1038/s41598-017-02811-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-02811-z</ArticleId><ArticleId IdType="pmc">PMC5462750</ArticleId><ArticleId IdType="pubmed">28592858</ArticleId></ArticleIdList></Reference><Reference><Citation>Sassani M., Alix J.J., McDermott C.J., Baster K., Hoggard N., Wild J.M., Mortiboys H.J., Shaw P.J., Wilkinson I.D., Jenkins T.M. Magnetic resonance spectroscopy reveals mitochondrial dysfunction in amyotrophic lateral sclerosis. Brain. 2021;143:3603&#x2013;3618. doi: 10.1093/brain/awaa340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa340</ArticleId><ArticleId IdType="pubmed">33439988</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri A., Lanfranconi F., Corna G., Bonazzi R., Marchese S., Magnoni A., Tremolizzo L. Tailored Exercise Training Counteracts Muscle Disuse and Attenuates Reductions in Physical Function in Individuals with Amyotrophic Lateral Sclerosis. Front. Physiol. 2019;10 doi: 10.3389/fphys.2019.01537.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2019.01537</ArticleId><ArticleId IdType="pmc">PMC6939659</ArticleId><ArticleId IdType="pubmed">31920728</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C., Lizio A., Sansone V.A., Cellotto N.M., Maestri E., Bettinelli M., Gatti V., Melazzini M.G., Meola G., Corbo M. Strictly monitored exercise programs reduce motor deterioration in ALS: Preliminary results of a randomized controlled trial. J. Neurol. 2016;263:52&#x2013;60. doi: 10.1007/s00415-015-7924-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-015-7924-z</ArticleId><ArticleId IdType="pubmed">26477027</ArticleId></ArticleIdList></Reference><Reference><Citation>Merico A., Cavinato M., Gregorio C., Lacatena A., Gioia E., Piccione F., Angelini C. Effects of combined endurance and resistance training in Amyotrophic Lateral Sclerosis: A pilot, randomized, controlled study. Eur. J. Transl. Myol. 2018;28:132&#x2013;140. doi: 10.4081/ejtm.2018.7278.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/ejtm.2018.7278</ArticleId><ArticleId IdType="pmc">PMC5895987</ArticleId><ArticleId IdType="pubmed">29686818</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsitkanou S., Della Gatta P., Foletta V., Russell A. The Role of Exercise as a Non-pharmacological Therapeutic Approach for Amyotrophic Lateral Sclerosis: Beneficial or detrimental? Front. Neurol. 2019;10:783. doi: 10.3389/fneur.2019.00783.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00783</ArticleId><ArticleId IdType="pmc">PMC6652799</ArticleId><ArticleId IdType="pubmed">31379732</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Haas V.D., Florence J.M., Kloos A.D., Scheirbecker J., Lopate G., Hayes S.M., Pioro E.P., Mitsumoto H. A randomized controlled trial of resistance exercise in individuals with ALS. Neurology. 2007;68:2003&#x2013;2007. doi: 10.1212/01.wnl.0000264418.92308.a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000264418.92308.a4</ArticleId><ArticleId IdType="pubmed">17548549</ArticleId></ArticleIdList></Reference><Reference><Citation>Drory V.E., Goltsman E., Goldman Reznik J., Mosek A., Korczyn A.D. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 2001;191:133&#x2013;137. doi: 10.1016/S0022-510X(01)00610-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(01)00610-4</ArticleId><ArticleId IdType="pubmed">11677004</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen L., Djurtoft J.B., Bech R.D., Nielsen J.L., J&#xf8;rgensen L.H., Schr&#xf8;der H.D., Frandsen U., Aagaard P., Hvid L.G. Influence of Resistance Training on Neuromuscular Function and Physical Capacity in ALS Patients. J. Neurodegener. Dis. 2017;2017:1436519. doi: 10.1155/2017/1436519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/1436519</ArticleId><ArticleId IdType="pmc">PMC5449732</ArticleId><ArticleId IdType="pubmed">28596929</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanjak M., Bravver E., Bockenek W.L., Norton H.J., Brooks B.R. Supported treadmill ambulation for amyotrophic lateral sclerosis: A pilot study. Arch. Phys. Med. Rehabil. 2010;91:1920&#x2013;1929. doi: 10.1016/j.apmr.2010.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apmr.2010.08.009</ArticleId><ArticleId IdType="pubmed">21112435</ArticleId></ArticleIdList></Reference><Reference><Citation>Braga A.C.M., Pinto A., Pinto S., De Carvalho M. The role of moderate aerobic exercise as determined by cardiopulmonary exercise testing in ALS. Neurol. Res. Int. 2018;2018:8218697. doi: 10.1155/2018/8218697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/8218697</ArticleId><ArticleId IdType="pmc">PMC5832023</ArticleId><ArticleId IdType="pubmed">29666705</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>